Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPDP: phMRI Biomarker in Parkinson's
NCT03205956Phase 1Completed
- Start
- Oct 2017
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of levodopa in Parkinson's disease (PD). Primary endpoint: Effect site rate constant Ke measured by phMRI at 2 hours. Started Oct 2017; status: completed.
02
Drugs
levodopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03205956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03205956.